|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, our studies led to identification of some key candidate genes, namely IRF2, IL6, IFNGR2, STAT4 and IL4RA that modulate genetic susceptibility to asthma in the Indian population.
|
25994869 |
2015 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Moreover, experimental subcutaneous immunotherapy (SIT) in T-bet((-/-)) mice inhibited IL-6, IL-21R and lung T(H17) cells in a setting of asthma.
|
23628948 |
2013 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Proinflammatory cytokines IL-6 and IL-8 are related to steroid-insensitive asthma.
|
30623574 |
2019 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Cases showed significant higher frequency of the genotypes: IL-6-174 GG (P<0.05, OR=3.2, 95% CI=1.09-10) that was evident mainly in the uncontrolled asthma subgroup indicative of the possibility of being a severity genotype.
|
18810365 |
2008 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Other inflammatory pathways are also emerging as implicated in asthma and COPD molecular phenotypes, including Type one and Type 17 adaptive immune responses and proinflammatory cytokines, such as interleukin-6.
|
31714272 |
2020 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Glucocorticoids activated the glucocorticoid receptor and inhibited serum-induced secretion of interleukin-6 in bronchial smooth-muscle cells from both subjects with asthma and those without asthma; however, glucocorticoids inhibited proliferation only in bronchial smooth-muscle cells from subjects without asthma.
|
15295049 |
2004 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MDM galectin-3 secretion was lower in asthma (9.99 (2.67, 15.48) ng/mL) compared with the healthy controls (20.72 (11.28, 27.89) ng/mL; p = 0.044) while IL-6 and CXCL8 levels were similar.
|
30606211 |
2019 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Th-17 regulatory cytokines IL-21, IL-23, and IL-6 enhance neutrophil production of IL-17 cytokines during asthma.
|
28635548 |
2017 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The group with both asthma and OSA had higher CRP, higher IL-6, a longer sleeping time in stage N1 sleep and stage N2 sleep, and less time in stage R sleep than the control group with no asthma or OSA.
|
29394961 |
2018 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Asthma was increased in Denmark (9%) compared to Greenland (3.6%, p < 0.0001) and associated with increased adipose tissue IL-6 gene expression and increased BMI.
|
26764119 |
2016 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The transcriptional induction of IL-6 was differentially regulated via C/EBP in the asthmatic and NF-kappaB + AP-1 in the non-asthmatic HASM cells.
|
16670028 |
2006 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Compared to controls, patients with acute exacerbation of bronchial asthma showed significantly lower adiponectin and significantly higher IL-6 and TNF-α levels (p<0.01).
|
26546898 |
2015 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Treatment of HASM cells with IL-6+sIL6R induced proliferation in a dose-dependent fashion, suggesting a role for IL-6 trans-signaling in asthma pathogenesis.
|
26001777 |
2015 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicate that IL-6 plays a pathogenic role in the HDM-induced asthma model and that lung macrophages and dendritic cells are the predominant sources of pathogenic IL-6 but contribute differently to the disease.
|
30534125 |
2018 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Airway smooth muscle (ASM) mass is increased in asthma, and ASM cells from patients with asthma are hyperproliferative and release more IL-6 and CXCL8.
|
25697361 |
2015 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The serum OX40L level showed a significant positive correlation with serum IgE, blood percentages of eosinophils and neutrophils, serum IL-6 and TSLP, and showed a negative correlation with asthma control test (ACT) score and forced expiratory volume in first second (FEV1%).
|
30890137 |
2019 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Budesonide was also able to reduce the release of IL-6 and TNF-α by PBMC of asthmatics.
|
25722071 |
2015 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Enhancement of IL-6 and IL-8 release may contribute to the deleterious effects of beta(2)-adrenoceptor agonists in asthma.
|
20423350 |
2010 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
IL-6-174C allele (P = 0.045), TNF-α-308GG genotype (P = 0.002) and TNF-α-308G allele (P = 0.004) showed reduced values, and TNF-α-308GA genotype (P = 0.002) increased FEF25-75 value in asthmatics.
|
21637953 |
2012 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
There was no association between IL-6 and MMP-9 with asthma duration, total IgE, AEC, number of allergens sensitized and degree of sensitization.
|
27780376 |
2017 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
IL-6 release was significantly increased in fibroblasts from mild and severe asthmatics compared to healthy controls.
|
29242170 |
2018 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A 10 μg/m<sup>3</sup> increase of NO<sub>2</sub> exposure during infancy was associated with a 13.6% (95% confidence interval (CI): 0.8; 28.1%) increase in interleukin-6 (IL-6) levels, as well as with a 27.8% (95% CI: 4.6, 56.2%) increase in IL-10 levels, the latter limited to children with asthma.
|
28669936 |
2017 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Both asthmatic PCOS and asthmatics expressed elevated BMI, IgE, IL-6 and CRP levels, but with no significant difference between them.
|
31496906 |
2019 |
|
Asthma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The airway epithelium is a major contributor to asthma pathology and has been shown to produce an excess of inflammatory and pro-remodelling cytokines such as TGF-β, IL-6 and IL-8 as well as deficient amounts of anti-viral interferons.
|
25360780 |
2014 |
|
Asthma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Dexamethasone's trans-activation of GILZ and trans-repression of NF-kB-driven IL-6 expression were both inhibited by IL2 + 4; IL17 + IL23 antagonized Dex trans-repression in PBMC from asthmatics.
|
23160983 |
2013 |